Contact Lenses and Infiltrative Keratitis

To quantify and compare baseline tear proteins and ocular response in contact lens wearers with a history of corneal infiltrative events, to those without a history of complications. This will be accomplished via measurement of select anti-inflammatory tear proteins before, during and after contact lens wear.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Keratitis Corneal Diseases Eye Diseases

Age range

18 year–30 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

SUNY College of Optometry, Clinical Vision Research Center

New York, 10036, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Soft contact lens wearers
Healthy (control), or with history of infiltrative keratitis (case)
Has a wearable pair of glasses
Refractive error between +8.00 D and -12.00 D, with less than 1.50 D of astigmatism

Exclusion criteria

Smoker
Pregnant or nursing
Systemic disease that would effect tear proteins
Punctal plugs
Use of eye drops in the last week

Treatment and study plan

Senofilcon A

Device

Other names: Acuvue Oasys

Primary outcomes

Tear protein levels

Time frame: After 4-6 hours of daily wear and after one night extended wear

Sponsors and collaborators

Lead sponsor

State University of New York College of Optometry

Other

Registry information

Acronym: CLIK

Important dates

Study start: 2014
Primary completion: 2016
Study completion: 2016
First posted: Jul 10, 2014
Registry last updated: Jul 12, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed